Add BrightSurf on Google Email

U-M hepatologist hails hepatitis B treatment trial results

Researchers have announced promising results of the B-Well clinical trials, showing that 20% and 19% of patients achieved a functional cure for their chronic hepatitis B infections after 24 weeks of bepirovirsen treatment. This represents a significant step towards developing a curative treatment for the disease.

SourceMichigan Medicine - University of Michigan·JournalNew England Journal of Medicine·TypeCommentary/editorial·DateMay 28, 2026

Extrahepatic autoimmune diseases in autoimmune hepatitis: their prevalence, predictors, and influence on early treatment outcomes

A study of 371 patients with autoimmune hepatitis (AIH) found that extrahepatic autoimmune diseases (EADs) are common, particularly Sjogren's syndrome and autoimmune thyroid disease. Patients with EADs had a poorer early treatment response but achieved comparable outcomes after six months.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 21, 2026

Team-based primary care strategy cuts hepatitis C virus treatment delays by four months

A family medicine interdisciplinary team improved hepatitis C virus treatment outcomes by streamlining medication access and reducing administrative burdens. The team's strategy, implemented at an urban clinic in Ohio, resulted in a significant reduction of treatment delays from over 6 months to under 2 months.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateJan 26, 2026

Although public overwhelmingly supports hepatitis B vaccine for a newborn, partisan differences exist

A national survey of adults found that three-quarters support vaccinating newborns against hepatitis B, but Republicans are less likely to recommend the vaccine. The survey also found that most respondents believe the vaccine protects against liver disease, and there is little evidence justifying delaying vaccination.

Fighting two infections at once

A study found that hepatitis C treatment with direct-acting antivirals (DAAs) improves immune function in individuals co-infected with HIV and HCV, even in those with advanced liver disease. The treatment resulted in significant declines in inflammation and liver damage markers.

SourceKyoto University·JournalJournal of Medical Virology·TypeRandomized controlled/clinical trial·DateNov 26, 2025

Autoimmune hepatitis associated with other autoimmune diseases

Autoimmune hepatitis is often associated with other autoimmune conditions, including thyroid disease, type 1 diabetes, inflammatory bowel disease, and rheumatologic disorders. The study highlights the need for precise diagnostic criteria and interdisciplinary management strategies to optimize outcomes in patients with multi-organ autoi...

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateNov 10, 2025

Khat-associated autoimmune hepatitis

This review synthesizes current knowledge on khat-associated autoimmune hepatitis, establishing a causal link and guiding clinical management. Khat use disrupts immune tolerance, leading to a chronic inflammatory state and the development of AIH-like phenotype in susceptible individuals.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateSep 30, 2025

New study in Ukraine indicates significant lifetime exposure and ongoing transmission of hepatitis B and C viruses among the general population

A nationwide study in Ukraine found substantial lifetime exposure to hepatitis B and C viruses, with significant ongoing circulation among the population. The study emphasizes the need for hepatitis B vaccination among infants and risk groups, as well as regular screening, treatment, and awareness-raising efforts.

The gut microbiota in elderly patients with acute hepatitis E infection

The study found that elderly patients with acute hepatitis E infection have distinct gut microbiota compositions compared to healthy controls. The relative abundance of Bacteroides fragilis was significantly associated with disease outcomes, including self-healing and non-self-healing cases. This suggests a potential role for Bacteroid...

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateJul 8, 2025

Pentoxifylline fails to improve survival in alcohol-associated hepatitis with kidney injury

A global study found that pentoxifylline has no mortality benefit in patients with severe alcohol-associated hepatitis and acute kidney injury. The study, which included 525 patients across 20 centers from eight countries, reaffirmed previous findings that cast doubt on the efficacy of pentoxifylline in alcoholic hepatitis.

SourceFirst Hospital of Jilin University·JournaleGastroenterology·DateMay 13, 2025

Patients with AMA/anti-sp100/anti-gp210 positivity and cholestasis can manifest conditions beyond primary biliary cholangitis

A study found that patients with AMA/anti-sp100/anti-gp210 positivity and elevated liver enzymes can manifest conditions beyond primary biliary cholangitis. Etiological treatments improved or resolved cholestatic biochemistry in these patients, justifying their initiation over ursodeoxycholic acid therapy.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateJan 23, 2025

Hepatitis E vaccination is effective in an epidemic

Researchers from UNIGE-HUG Centre and MSF successfully demonstrated the effectiveness of a hepatitis E vaccine in an outbreak in Bentiu, South Sudan. The study showed that two doses of the vaccine reduced the incidence of the disease and provided protection against severe symptoms.

SourceUniversité de Genève·JournalThe Lancet Infectious Diseases·TypeNews article·DateJan 14, 2025

Wild boars could be a potential source of hepatitis E transmission to humans in the Barcelona metropolitan area

A study by University of Barcelona researchers found a close molecular similarity between wild boar and human hepatitis E virus strains. The researchers recommend avoiding contact with wild boars, washing hands after contact, and taking precautions in areas frequented by pets to prevent transmission.

SourceUniversity of Barcelona·JournalScience of The Total Environment·TypeExperimental study·DateNov 26, 2024

Advances in the treatment of autoimmune hepatitis

Recent advancements in AIH pathogenesis have paved the way for novel therapeutic strategies, including treatments targeting the gut-liver axis and immune system dysregulation. Emerging biologics and immune-modulating drugs show promise in achieving biochemical remission in refractory cases.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateNov 6, 2024

Unraveling the link between hepatitis and kidney damage

Researchers from the University of Zurich have discovered a link between hepatitis E and kidney damage, finding that viral envelope-antibody complexes can accumulate in kidney filters and cause glomerulonephritis. The study uses tissue samples from patients to understand the disease mechanism.

SourceUniversity of Zurich·JournalNature Communications·TypeExperimental study·DateOct 31, 2024

Systematic evaluation of guidelines for the diagnosis and treatment of hepatitis E virus infection

The study evaluated 7 guidelines for the diagnosis and treatment of HEV infection, finding significant variability in quality and consistency. The guidelines scored poorly in areas such as stakeholder involvement, rigor of development, and applicability, highlighting the need for improvements.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateSep 13, 2024

An artificial hepatocyte growth factor mimetic ameliorates non-alcoholic steatohepatitis in mouse model

A research group developed a long-acting artificial hepatocyte growth factor (HGF) mimetic molecule using cyclic peptides and protein engineering. The molecule improved liver fibrosis, lipid accumulation, and inflammation in a mouse model with non-alcoholic steatohepatitis (NASH), providing an option for NASH therapeutics.

SourceNano Life Science Institute (NanoLSI), Kanazawa University·JournaliScience·TypeExperimental study·DateJul 26, 2024

First detection of hepatitis E virus from urban Norway rats (Rattus norvegicus) in the Republic of Korea

Researchers in South Korea have detected the first hepatitis E virus from urban Norway rats, raising concerns about potential human transmission. The study found that 4.4% of examined rats carried the virus, which is linked to symptoms like fever, fatigue, and jaundice in humans.

SourceKorea University College of Medicine·JournalJournal of Medical Virology·TypeExperimental study·DateMay 10, 2024

Echovirus 11 in newly born twins: case in Italy shows close genetic relation to strains found in France among neonates

A case of echovirus 11-induced hepatitis in Italian male twins has been reported, showing a close genetic relation to strains found in France among neonates. The study highlights the importance of rapid recognition and timely treatment to ensure survival, and suggests potential host genetic predisposition in male and twin categories.

Real-world studies confirm effectiveness of bulevirtide to treat chronic hepatitis D

Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.

SourceElsevier·JournalJournal of Hepatology·TypeExperimental study·DateMar 20, 2023

Journal of Pharmaceutical Analysis studies explore key traditional and modern therapeutics

Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateFeb 14, 2023